Empirical Asset Management LLC Sells 749 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Empirical Asset Management LLC cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 68.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 346 shares of the biopharmaceutical company’s stock after selling 749 shares during the period. Empirical Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $304,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of REGN. FMR LLC raised its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after buying an additional 669,517 shares during the last quarter. State Street Corp raised its holdings in shares of Regeneron Pharmaceuticals by 2.0% during the second quarter. State Street Corp now owns 4,990,870 shares of the biopharmaceutical company’s stock worth $3,586,140,000 after purchasing an additional 97,254 shares during the last quarter. Geode Capital Management LLC increased its holdings in Regeneron Pharmaceuticals by 2.8% in the second quarter. Geode Capital Management LLC now owns 2,281,129 shares of the biopharmaceutical company’s stock valued at $1,635,148,000 after buying an additional 63,136 shares in the last quarter. Northern Trust Corp increased its holdings in Regeneron Pharmaceuticals by 3.3% in the third quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock valued at $878,271,000 after buying an additional 34,326 shares in the last quarter. Finally, Morgan Stanley increased its holdings in Regeneron Pharmaceuticals by 2.7% in the third quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock valued at $799,061,000 after buying an additional 25,792 shares in the last quarter. 84.15% of the stock is currently owned by institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the sale, the director now directly owns 18,282 shares of the company’s stock, valued at $17,953,838.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the transaction, the director now owns 18,282 shares in the company, valued at $17,953,838.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,226 shares of company stock valued at $17,061,869. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.1 %

Regeneron Pharmaceuticals stock traded down $0.77 during trading on Friday, reaching $967.24. The company had a trading volume of 272,748 shares, compared to its average volume of 511,269. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33. The stock’s 50 day moving average price is $955.78 and its two-hundred day moving average price is $875.31. The firm has a market capitalization of $106.16 billion, a price-to-earnings ratio of 27.83, a PEG ratio of 2.78 and a beta of 0.11. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the previous year, the firm earned $10.96 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% on a year-over-year basis. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

REGN has been the topic of several research analyst reports. Royal Bank of Canada lifted their target price on shares of Regeneron Pharmaceuticals from $1,096.00 to $1,184.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. Truist Financial reissued a “buy” rating and issued a $1,045.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, December 18th. TD Cowen boosted their price target on shares of Regeneron Pharmaceuticals from $900.00 to $1,000.00 and gave the company an “outperform” rating in a research note on Wednesday, December 6th. Cantor Fitzgerald upped their target price on shares of Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 6th. Finally, Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $959.09.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.